Engineering the gut microbiota to treat chronic diseases

被引:0
作者
Noura S. Dosoky
Linda S. May-Zhang
Sean S. Davies
机构
[1] Vanderbilt University,Department of Pharmacology and Division of Clinical Pharmacology
来源
Applied Microbiology and Biotechnology | 2020年 / 104卷
关键词
Gut microbiota; Engineered bacteria; Cancer; Diabetes; Inflammatory bowel disease; Atherosclerosis; Obesity;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:7657 / 7671
页数:14
相关论文
共 804 条
[51]  
Drulhe S(2018)Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase Front Physiol 9 1534-1400
[52]  
Felicori L(2002)Free radicals and other reactive oxygen metabolites in inflammatory bowel disease: cause, consequence or epiphenomenon? Hum Gene Ther 13 1225-4276
[53]  
Fogg MJ(1995)Exogenous cytosine deaminase gene expression in Appl Environ Microbiol 61 2771-296
[54]  
Goelzer A(2016) I-53-8w for tumor-targeting enzyme/prodrug therapy Oncotarget. 7 22605-36
[55]  
Hansen A(2017)The use of bacterial spore formers as probiotics Cell Syst 4 291-32
[56]  
Harwood CR(2015)Biological containment of genetically modified Res Microbiol 166 244-1105
[57]  
Hecker M(2011)Industrial production of recombinant therapeutics in J Biotechnol 151 287-478
[58]  
Hubner S(2005) and its recent advancements Cancer Gene Ther 12 175-8381
[59]  
Hultschig C(2013)Induction of ovalbumin-specific tolerance by oral administration of J Control Release 170 120-3266
[60]  
Jarmer H(1997) secreting ovalbumin Gene Ther 8 791-1128